Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
Journal of the National Cancer Institute
|
March 31, 2021
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer
Nuria Chic, Stephen J Luen, Paolo Nuciforo, et al.
Oncotarget
|
September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Breast Cancer Research : BCR
|
October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Serena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
The Lancet. Oncology
|
June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
Sherene Loi, W Fraser Symmans, John M S Bartlett, et al.
BMC Genomics
|
November 22, 2014
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
Debora Fumagalli, Alexis Blanchet-Cohen, David Brown, et al.
JAMA Oncology
|
June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Ryan L Powles, David Redmond, Christos Sotiriou, et al.
Genome Biology
|
October 2, 2014
Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
Ingrid M Lönnstedt, Franco Caramia, Jason Li, et al.
British Journal of Cancer
|
April 8, 2021
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
José Bines, Emma Clark, Claire Barton, et al.
Anti-Cancer Drugs
|
July 16, 2019
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
Yang Luo, Wei Li, Zefei Jiang, et al.
Cancer Chemotherapy and Pharmacology
|
April 13, 2019
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Whitney P Kirschbrown, Matts Kågedal, Bei Wang, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
Journal of the National Cancer Institute
|
March 31, 2021
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer
Nuria Chic, Stephen J Luen, Paolo Nuciforo, et al.
Oncotarget
|
September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Breast Cancer Research : BCR
|
October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Serena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
The Lancet. Oncology
|
June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
Sherene Loi, W Fraser Symmans, John M S Bartlett, et al.
BMC Genomics
|
November 22, 2014
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
Debora Fumagalli, Alexis Blanchet-Cohen, David Brown, et al.
JAMA Oncology
|
June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Ryan L Powles, David Redmond, Christos Sotiriou, et al.
Genome Biology
|
October 2, 2014
Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
Ingrid M Lönnstedt, Franco Caramia, Jason Li, et al.
British Journal of Cancer
|
April 8, 2021
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
José Bines, Emma Clark, Claire Barton, et al.
Anti-Cancer Drugs
|
July 16, 2019
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
Yang Luo, Wei Li, Zefei Jiang, et al.
Cancer Chemotherapy and Pharmacology
|
April 13, 2019
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Whitney P Kirschbrown, Matts Kågedal, Bei Wang, et al.
Page
of 7